{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:23:16Z","timestamp":1790997796424,"version":"4.1.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s13300-025-01733-8","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T23:44:15Z","timestamp":1746575055000},"page":"1207-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2354-6279","authenticated-orcid":false,"given":"\u0160pela","family":"Vol\u010dan\u0161ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7407-9732","authenticated-orcid":false,"given":"Andrijana","family":"Koceva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-8803","authenticated-orcid":false,"given":"Mojca","family":"Jensterle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-5254","authenticated-orcid":false,"given":"Andrej","family":"Jane\u017e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-3298","authenticated-orcid":false,"given":"Emir","family":"Muzurovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"1733_CR1","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.cell.2024.06.029","volume":"187","author":"ED Abel","year":"2024","unstructured":"Abel ED, Gloyn AL, Evans-Molina C, et al. Diabetes mellitus-progress and opportunities in the evolving epidemic. Cell. 2024;187:3789\u2013820.","journal-title":"Cell"},{"key":"1733_CR2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1007\/s00125-020-05211-7","volume":"63","author":"MJ Redondo","year":"2020","unstructured":"Redondo MJ, Hagopian WA, Oram R, et al. The clinical consequences of heterogeneity within and between different diabetes types. Diabetologia. 2020;63:2040\u20138.","journal-title":"Diabetologia"},{"key":"1733_CR3","doi-asserted-by":"crossref","unstructured":"Leslie RD, Ma RCW, Franks PW, Nadeau KJ, Pearson ER, Redondo MJ. Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes. Lancet Diabetes Endocrinol. 2023;11:848\u201360. https:\/\/www.thelancet.com\/journals\/landia\/article\/PIIS2213-8587(23)00159-6\/abstract.","DOI":"10.1016\/S2213-8587(23)00159-6"},{"key":"1733_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3005","volume":"34","author":"JV Stidsen","year":"2018","unstructured":"Stidsen JV, Henriksen JE, Olsen MH.., et al. Pathophysiology-based phenotyping in type 2 diabetes: a clinical classification tool. Diabetes Metab Res Rev. 2018;34:e3005.","journal-title":"Diabetes Metab Res Rev"},{"key":"1733_CR5","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","volume":"66","author":"DJ Drucker","year":"2023","unstructured":"Drucker DJ, Holst JJ. The expanding incretin universe: from basic biology to clinical translation. Diabetologia. 2023;66:1765\u201379.","journal-title":"Diabetologia"},{"key":"1733_CR6","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s00125-023-05980-x","volume":"66","author":"C Mathieu","year":"2023","unstructured":"Mathieu C, Ahmadzai I. Incretins beyond type 2 diabetes. Diabetologia. 2023;66:1809\u201319. https:\/\/doi.org\/10.1007\/s00125-023-05980-x.","journal-title":"Diabetologia"},{"key":"1733_CR7","doi-asserted-by":"crossref","unstructured":"Aberer F, Pieber TR, Eckstein ML, Sourij H, Moser O. Glucose-lowering therapy beyond insulin in type 1 diabetes: a narrative review on existing evidence from randomized controlled trials and clinical perspective. Pharmaceutics. 2022;14:1180. https:\/\/www.mdpi.com\/1999-4923\/14\/6\/1180.","DOI":"10.3390\/pharmaceutics14061180"},{"key":"1733_CR8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","volume":"66","author":"M Anson","year":"2023","unstructured":"Anson M, Zhao SS, Austin P, Ibarburu GH, Malik RA, Alam U. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia. 2023;66:1869\u201381.","journal-title":"Diabetologia"},{"key":"1733_CR9","unstructured":"International Diabetes Federation. IDF diabetes atlas. Type 1 diabetes estimates in children and adults. https:\/\/diabetesatlas.org\/atlas\/t1d-index-2022\/. Accessed"},{"key":"1733_CR10","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/dci21-0043","volume":"44","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of Type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021;44:2589\u2013625. https:\/\/doi.org\/10.2337\/dci21-0043.","journal-title":"Diabetes Care"},{"key":"1733_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155402","volume":"141","author":"B Chong","year":"2023","unstructured":"Chong B, Kong G, Shankar K, et al. The global syndemic of metabolic diseases in the young adult population: a consortium of trends and projections from the Global Burden of Disease 2000\u20132019. Metabolism. 2023;141: 155402.","journal-title":"Metabolism"},{"key":"1733_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.diabres.2014.10.007","volume":"107","author":"ER F\u00e4hrmann","year":"2015","unstructured":"F\u00e4hrmann ER, Adkins L, Loader CJ, et al. Severe hypoglycemia and coronary artery calcification during the diabetes control and complications trial\/epidemiology of diabetes interventions and complications (DCCT\/EDIC) study. Diabetes Res Clin Pract. 2015;107:280\u20139.","journal-title":"Diabetes Res Clin Pract"},{"key":"1733_CR13","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","volume":"371","author":"M Lind","year":"2014","unstructured":"Lind M, Svensson A-M, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371:1972\u201382.","journal-title":"N Engl J Med"},{"key":"1733_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/dom.14218","volume":"23","author":"B Coles","year":"2021","unstructured":"Coles B, Zaccardi F, Hvid C, Davies MJ, Khunti K. Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: a real-world study of patients followed for up to 19 years. Diabetes Obes Metab. 2021;23:218\u201327.","journal-title":"Diabetes Obes Metab"},{"issue":"48","key":"1733_CR15","first-page":"289","volume":"2024","author":"MTW Kueh","year":"2005","unstructured":"Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes. 2005;2024(48):289\u2013301.","journal-title":"Int J Obes"},{"key":"1733_CR16","doi-asserted-by":"crossref","unstructured":"Bl\u00fcher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288\u201398. https:\/\/www.nature.com\/articles\/s41574-019-0176-8","DOI":"10.1038\/s41574-019-0176-8"},{"key":"1733_CR17","doi-asserted-by":"publisher","first-page":"204201882093495","DOI":"10.1177\/2042018820934955","volume":"11","author":"S Ansari","year":"2020","unstructured":"Ansari S, Haboubi H, Haboubi N. Adult obesity complications: challenges and clinical impact. Ther Adv Endocrinol Metab. 2020;11:2042018820934955.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1733_CR18","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.2147\/DMSO.S223618","volume":"14","author":"N Vilarrasa","year":"2021","unstructured":"Vilarrasa N, San Jose P, Rubio M\u00c1, Lecube A. Obesity in patients with type 1 diabetes: links, risks and management challenges. Diabetes Metab Syndr Obes Targets Ther. 2021;14:2807\u201327.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"1733_CR19","first-page":"1","volume":"31","author":"M Freeby","year":"2024","unstructured":"Freeby M, Lane K. Treating obesity in type 1 diabetes mellitus\u2014review of efficacy and safety. Curr Opin Endocrinol Diabetes Obes. 2024;31:1\u20137.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1733_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2022.07.017","volume":"365","author":"A Janez","year":"2022","unstructured":"Janez A, Muzurovic E, Stoian AP, et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol. 2022;365:8\u201318.","journal-title":"Int J Cardiol"},{"key":"1733_CR21","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s13300-024-01615-5","volume":"15","author":"A Janez","year":"2024","unstructured":"Janez A, Muzurovic E, Bogdanski P, et al. Modern management of cardiometabolic continuum: from overweight\/obesity to prediabetes\/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe diabetes and obesity expert group. Diabetes Ther. 2024;15:1865\u201392. https:\/\/doi.org\/10.1007\/s13300-024-01615-5.","journal-title":"Diabetes Ther"},{"key":"1733_CR22","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1210\/jc.2011-0585","volume":"96","author":"RH Eckel","year":"2011","unstructured":"Eckel RH, Kahn SE, Ferrannini E, et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011;96:1654\u201363.","journal-title":"J Clin Endocrinol Metab"},{"key":"1733_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12933-024-02145-x","volume":"23","author":"W Bielka","year":"2024","unstructured":"Bielka W, Przezak A, Mol\u0119da P, Pius-Sadowska E, Machali\u0144ski B. Double diabetes\u2014when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition. Cardiovasc Diabetol. 2024;23:62.","journal-title":"Cardiovasc Diabetol"},{"key":"1733_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.838410","volume":"13","author":"Q Tan","year":"2022","unstructured":"Tan Q, Akindehin SE, Orsso CE, et al. Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes. Front Endocrinol. 2022;13: 838410.","journal-title":"Front Endocrinol"},{"key":"1733_CR25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/nyas.14211","volume":"1461","author":"CW Chia","year":"2020","unstructured":"Chia CW, Egan JM. Incretins in obesity and diabetes. Ann N Y Acad Sci. 2020;1461:104\u201326.","journal-title":"Ann N Y Acad Sci"},{"key":"1733_CR26","doi-asserted-by":"publisher","first-page":"107424842211463","DOI":"10.1177\/10742484221146371","volume":"27","author":"EM Muzurovi\u0107","year":"2022","unstructured":"Muzurovi\u0107 EM, Vol\u010dan\u0161ek \u0160, Tom\u0161i\u0107 KZ, et al. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonists in the treatment of obesity\/metabolic syndrome, prediabetes\/diabetes and non-alcoholic fatty liver disease-current evidence. J Cardiovasc Pharmacol Ther. 2022;27:10742484221146372.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"1733_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","volume":"15","author":"RM Gutgesell","year":"2024","unstructured":"Gutgesell RM, Nogueiras R, Tsch\u00f6p MH, M\u00fcller TD. Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes. Diabetes Ther. 2024;15:1069\u201384. https:\/\/doi.org\/10.1007\/s13300-024-01566-x.","journal-title":"Diabetes Ther."},{"key":"1733_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13300-022-01360-7","volume":"14","author":"M Jensterle","year":"2023","unstructured":"Jensterle M, Rizzo M, Jane\u017e A. Semaglutide in obesity: unmet needs in men. Diabetes Ther. 2023;14:461\u20135.","journal-title":"Diabetes Ther"},{"key":"1733_CR29","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pr.115.010629","volume":"67","author":"DL Hay","year":"2015","unstructured":"Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67:564\u2013600.","journal-title":"Pharmacol Rev"},{"key":"1733_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2022.105965","volume":"172","author":"TA Lutz","year":"2022","unstructured":"Lutz TA. Creating the amylin story. Appetite. 2022;172:105965.","journal-title":"Appetite"},{"key":"1733_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1463-1326.2012.01670.x","volume":"15","author":"TA Lutz","year":"2013","unstructured":"Lutz TA. The interaction of amylin with other hormones in the control of eating. Diabetes Obes Metab. 2013;15:99\u2013111.","journal-title":"Diabetes Obes Metab"},{"key":"1733_CR32","doi-asserted-by":"publisher","first-page":"47S","DOI":"10.1177\/0145721715607642","volume":"41","author":"L Hieronymus","year":"2015","unstructured":"Hieronymus L, Griffin S. Role of amylin in type 1 and type 2 diabetes. Diabetes Educ. 2015;41:47S-56S.","journal-title":"Diabetes Educ"},{"key":"1733_CR33","doi-asserted-by":"crossref","unstructured":"Bower RL, Hay DL. Amylin structure\u2013function relationships and receptor pharmacology: implications for amylin mimetic drug development. Br J Pharmacol. 2016;173:1883. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4882495\/.","DOI":"10.1111\/bph.13496"},{"key":"1733_CR34","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1073\/pnas.84.23.8628","volume":"84","author":"GJ Cooper","year":"1987","unstructured":"Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 1987;84:8628\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1733_CR35","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0140-6736(87)90825-7","volume":"330","author":"A Clark","year":"1987","unstructured":"Clark A, Lewis CE, Willis AC, Cooper GJS, Morris JF, Reid KBM, et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet. 1987;330:231\u20134.","journal-title":"Lancet"},{"key":"1733_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpc.2024.107285","volume":"312","author":"Z Dai","year":"2024","unstructured":"Dai Z, Ben-Younis A, Vlachaki A, Raleigh D, Thalassinos K. Understanding the structural dynamics of human islet amyloid polypeptide: advancements in and applications of ion-mobility mass spectrometry. Biophys Chem. 2024;312:107285.","journal-title":"Biophys Chem"},{"key":"1733_CR37","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1021\/acs.biochem.5b00567","volume":"54","author":"H Wang","year":"2015","unstructured":"Wang H, Ridgway Z, Cao P, Ruzsicska B, Raleigh DP. Analysis of the ability of pramlintide to inhibit amyloid formation by human islet amyloid polypeptide reveals a balance between optimal recognition and reduced amyloidogenicity. Biochemistry. 2015;54:6704\u201311.","journal-title":"Biochemistry"},{"key":"1733_CR38","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00018-011-0905-1","volume":"69","author":"TA Lutz","year":"2012","unstructured":"Lutz TA. Control of energy homeostasis by amylin. Cell Mol Life Sci. 2012;69:1947\u201365.","journal-title":"Cell Mol Life Sci"},{"key":"1733_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s001250050646","volume":"40","author":"MF Kong","year":"1997","unstructured":"Kong MF, King P, Macdonald IA, et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997;40:82\u20138.","journal-title":"Diabetologia"},{"key":"1733_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm9609","volume":"375","author":"J Cao","year":"2022","unstructured":"Cao J, Belousoff MJ, Liang Y-L, et al. A structural basis for amylin receptor phenotype. Science. 2022;375: eabm9609.","journal-title":"Science"},{"key":"1733_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bph.14075","volume":"175","author":"DL Hay","year":"2018","unstructured":"Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR review 25. Br J Pharmacol. 2018;175:3\u201317.","journal-title":"Br J Pharmacol"},{"key":"1733_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113842","volume":"156","author":"AT Larsen","year":"2022","unstructured":"Larsen AT, Mohamed KE, Sonne N, Bredtoft E, Andersen F, Karsdal MA, et al. Does receptor balance matter?\u2014Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomed Pharmacother. 2022;156: 113842.","journal-title":"Biomed Pharmacother"},{"key":"1733_CR43","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.2337\/db19-0849","volume":"69","author":"B Coester","year":"2020","unstructured":"Coester B, Koester-Hegmann C, Lutz TA, Le Foll C. Amylin\/calcitonin receptor-mediated signaling in POMC neurons influences energy balance and locomotor activity in chow-fed male mice. Diabetes. 2020;69:1110\u201325.","journal-title":"Diabetes"},{"key":"1733_CR44","doi-asserted-by":"crossref","unstructured":"Hay DL, Pioszak AA. RAMPs (Receptor-Activity Modifying Proteins): new insights and roles. Annu Rev Pharmacol Toxicol. 2015;56:469. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5559101\/.","DOI":"10.1146\/annurev-pharmtox-010715-103120"},{"key":"1733_CR45","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/ijms25031517","volume":"25","author":"S Er\u017een","year":"2024","unstructured":"Er\u017een S, Tonin G, Juri\u0161i\u0107 Er\u017een D, Klen J. Amylin, another important neuroendocrine hormone for the treatment of diabesity. Int J Mol Sci. 2024;25:1517.","journal-title":"Int J Mol Sci"},{"key":"1733_CR46","doi-asserted-by":"crossref","unstructured":"Garelja ML, Hay D, Poyner DR, Walker CS. Calcitonin receptors in GtoPdb v.2023.1. IUPHARBPS guide to pharmacology CITE. 2023. http:\/\/journals.ed.ac.uk\/gtopdb-cite\/article\/view\/8664. Accessed 3 Mar 2025.","DOI":"10.2218\/gtopdb\/F11\/2023.1"},{"key":"1733_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7570\/jomes21071","volume":"30","author":"B Dehestani","year":"2021","unstructured":"Dehestani B, Stratford NR, Roux CWL. Amylin as a future obesity treatment. J Obes Metab Syndr. 2021;30:320\u20135.","journal-title":"J Obes Metab Syndr"},{"key":"1733_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3233\/JAD-180433","volume":"66","author":"J Grizzanti","year":"2018","unstructured":"Grizzanti J, Corrigan R, Casadesus G. Neuroprotective effects of amylin analogues on Alzheimer\u2019s disease pathogenesis and cognition. J Alzheimers Dis. 2018;66:11\u201323.","journal-title":"J Alzheimers Dis"},{"key":"1733_CR49","unstructured":"Chwalba A, Dudek A, Otto-Buczkowska E. Role of amylin in glucose homeostasis. Austin Diabetes Res. 2019;4(1): 1021."},{"key":"1733_CR50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","volume":"46","author":"BR Gedulin","year":"1997","unstructured":"Gedulin BR, Rink TJ, Young AA. Dose-response for glucagonostatic effect of amylin in rats. Metabolism. 1997;46:67\u201370.","journal-title":"Metabolism"},{"key":"1733_CR51","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.3390\/jcm11082207","volume":"11","author":"CN Boyle","year":"2022","unstructured":"Boyle CN, Zheng Y, Lutz TA. Mediators of amylin action in metabolic control. J Clin Med. 2022;11:2207.","journal-title":"J Clin Med"},{"key":"1733_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0026-0495(96)90192-4","volume":"45","author":"AA Young","year":"1996","unstructured":"Young AA, Gedulin BR, Rink TJ. Preliminary report Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7\u201336)NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism. 1996;45:1\u20133.","journal-title":"Metabolism"},{"key":"1733_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2337\/diab.47.1.93","volume":"47","author":"BR Gedulin","year":"1998","unstructured":"Gedulin BR, Young AA. Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes. 1998;47:93\u20137.","journal-title":"Diabetes"},{"key":"1733_CR54","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.physbeh.2006.04.001","volume":"89","author":"TA Lutz","year":"2006","unstructured":"Lutz TA. Amylinergic control of food intake. Physiol Behav. 2006;89:465\u201371.","journal-title":"Physiol Behav"},{"key":"1733_CR55","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2337\/diabetes.49.6.961","volume":"49","author":"LL Ilag","year":"2000","unstructured":"Ilag LL, Tabaei BP, Herman WH, et al. Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with a mutation in the HNF-4alpha\/MODY1 gene. Diabetes. 2000;49:961\u20138.","journal-title":"Diabetes"},{"key":"1733_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pcad.2024.03.004","volume":"85","author":"K Ze\u010devi\u0107","year":"2024","unstructured":"Ze\u010devi\u0107 K, Vol\u010dan\u0161ek \u0160, Katsiki N, et al. Maturity-onset diabetes of the young (MODY)\u2014in search of ideal diagnostic criteria and precise treatment. Prog Cardiovasc Dis. 2024;85:14\u201325.","journal-title":"Prog Cardiovasc Dis"},{"key":"1733_CR57","doi-asserted-by":"crossref","unstructured":"Young A. Inhibition of glucagon secretion. Adv Pharmacol. 2005;52:151\u201371. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358905520088.","DOI":"10.1016\/S1054-3589(05)52008-8"},{"key":"1733_CR58","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1055\/s-2002-34790","volume":"34","author":"M Fineman","year":"2002","unstructured":"Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res. 2002;34:504\u20138.","journal-title":"Horm Metab Res"},{"key":"1733_CR59","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1053\/meta.2002.32022","volume":"51","author":"MS Fineman","year":"2002","unstructured":"Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism. 2002;51:636\u201341.","journal-title":"Metabolism"},{"key":"1733_CR60","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/14656566.2024.2356254","volume":"25","author":"P Gogineni","year":"2024","unstructured":"Gogineni P, Melson E, Papamargaritis D, Davies M. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? Expert Opin Pharmacother. 2024;25:801\u201318.","journal-title":"Expert Opin Pharmacother"},{"key":"1733_CR61","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1056\/NEJMra2020927","volume":"384","author":"RK Goyal","year":"2021","unstructured":"Goyal RK. Gastric emptying abnormalities in diabetes mellitus. N Engl J Med. 2021;384:1742\u201351.","journal-title":"N Engl J Med"},{"key":"1733_CR62","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00125-022-05796-1","volume":"65","author":"RJ Jalleh","year":"2022","unstructured":"Jalleh RJ, Jones KL, Rayner CK, Marathe CS, Wu T, Horowitz M. Normal and disordered gastric emptying in diabetes: recent insights into (patho)physiology, management and impact on glycaemic control. Diabetologia. 2022;65:1981\u201393. https:\/\/doi.org\/10.1007\/s00125-022-05796-1.","journal-title":"Diabetologia"},{"key":"1733_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","volume":"8","author":"CN Boyle","year":"2018","unstructured":"Boyle CN, Lutz TA, Le Foll C. Amylin\u2014Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity. Mol Metab. 2018;8:203\u201310.","journal-title":"Mol Metab"},{"key":"1733_CR64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bcpt.13427","volume":"127","author":"HL Zakariassen","year":"2020","unstructured":"Zakariassen HL, John LM, Lutz TA. Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases. Basic Clin Pharmacol Toxicol. 2020;127:163\u201377.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1733_CR65","doi-asserted-by":"publisher","first-page":"R1475","DOI":"10.1152\/ajpregu.00703.2009","volume":"298","author":"TA Lutz","year":"2010","unstructured":"Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Physiol. 2010;298:R1475\u201384.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1733_CR66","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/0031-9384(95)02067-5","volume":"58","author":"T Lutz","year":"1995","unstructured":"Lutz T. Amylin decreases meal size in rats. Physiol Behav. 1995;58:1197\u2013202.","journal-title":"Physiol Behav"},{"key":"1733_CR67","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.biopsych.2023.07.011","volume":"95","author":"CE Geisler","year":"2024","unstructured":"Geisler CE, D\u00e9carie-Spain L, Loh MK, et al. Amylin modulates a ventral tegmental area\u2013to\u2013medial prefrontal cortex circuit to suppress food intake and impulsive food-directed behavior. Biol Psychiatry. 2024;95:938\u201350.","journal-title":"Biol Psychiatry"},{"key":"1733_CR68","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1113\/EP088356","volume":"105","author":"H Nashawi","year":"2020","unstructured":"Nashawi H, Gustafson TJ, Mietlicki-Baase EG. Palatable food access impacts expression of amylin receptor components in the mesocorticolimbic system. Exp Physiol. 2020;105:1012\u201324.","journal-title":"Exp Physiol"},{"key":"1733_CR69","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.neuroimage.2007.11.008","volume":"39","author":"G-J Wang","year":"2008","unstructured":"Wang G-J, Tomasi D, Backus W, Wang R, Telang F, Geliebter A, et al. Gastric distention activates satiety circuitry in the human brain. Neuroimage. 2008;39:1824\u201331.","journal-title":"Neuroimage"},{"key":"1733_CR70","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/oby.2002.147","volume":"10","author":"TK Reda","year":"2002","unstructured":"Reda TK, Geliebter A, Pi-Sunyer FX. Amylin, food intake, and obesity. Obes Res. 2002;10:1087\u201391.","journal-title":"Obes Res"},{"key":"1733_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.physbeh.2010.04.012","volume":"101","author":"PY Wielinga","year":"2010","unstructured":"Wielinga PY, L\u00f6wenstein C, Muff S, Munz M, Woods SC, Lutz TA. Central amylin acts as an adiposity signal to control body weight and energy expenditure. Physiol Behav. 2010;101:45\u201352.","journal-title":"Physiol Behav"},{"key":"1733_CR72","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.peptides.2008.02.002","volume":"29","author":"T Osaka","year":"2008","unstructured":"Osaka T, Tsukamoto A, Koyama Y, Inoue S. Central and peripheral administration of amylin induces energy expenditure in anesthetized rats. Peptides. 2008;29:1028\u201335.","journal-title":"Peptides"},{"key":"1733_CR73","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1210\/en.2012-2172","volume":"154","author":"C Fernandes-Santos","year":"2013","unstructured":"Fernandes-Santos C, Zhang Z, Morgan DA, Guo D-F, Russo AF, Rahmouni K. Amylin acts in the central nervous system to increase sympathetic nerve activity. Endocrinology. 2013;154:2481\u20138.","journal-title":"Endocrinology"},{"key":"1733_CR74","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.3390\/ijms24108592","volume":"24","author":"T Hropot","year":"2023","unstructured":"Hropot T, Herman R, Janez A, Lezaic L, Jensterle M. Brown adipose tissue: a new potential target for glucagon-like peptide 1 receptor agonists in the treatment of obesity. Int J Mol Sci. 2023;24:8592.","journal-title":"Int J Mol Sci"},{"key":"1733_CR75","first-page":"E156","volume":"267","author":"TR Pieber","year":"1994","unstructured":"Pieber TR, Roitelman J, Lee Y, Luskey KL, Stein DT. Direct plasma radioimmunoassay for rat amylin-(1\u201337): concentrations with acquired and genetic obesity. Am J Physiol. 1994;267:E156-164.","journal-title":"Am J Physiol"},{"key":"1733_CR76","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/978-3-642-24716-3_10","volume-title":"Appetite control","author":"TA Lutz","year":"2012","unstructured":"Lutz TA. Effects of amylin on eating and adiposity. In: Joost H-G, editor. Appetite control. Berlin Heidelberg: Springer; 2012. p. 231\u201350. https:\/\/doi.org\/10.1007\/978-3-642-24716-3_10."},{"key":"1733_CR77","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1073\/pnas.0706473105","volume":"105","author":"JD Roth","year":"2008","unstructured":"Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA. 2008;105:7257\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1733_CR78","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1530\/JOE-19-0201","volume":"243","author":"JH Stern","year":"2019","unstructured":"Stern JH, Smith GI, Chen S, Unger RH, Klein S, Scherer PE. Obesity dysregulates fasting-induced changes in glucagon secretion. J Endocrinol. 2019;243:149\u201360.","journal-title":"J Endocrinol"},{"key":"1733_CR79","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.clinthera.2021.08.006","volume":"43","author":"C-X Lu","year":"2021","unstructured":"Lu C-X, An X-X, Yu Y, Jiao L-R, Canarutto D, Li G-F, et al. Pooled analysis of gastric emptying in patients with obesity: implications for oral absorption projection. Clin Ther. 2021;43:1768\u201388.","journal-title":"Clin Ther"},{"key":"1733_CR80","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1210\/en.2006-0393","volume":"147","author":"JD Roth","year":"2006","unstructured":"Roth JD, Hughes H, Kendall E, Baron AD, Anderson CM. Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology. 2006;147:5855\u201364.","journal-title":"Endocrinology"},{"key":"1733_CR81","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1440-1681.1998.tb02272.x","volume":"25","author":"PJ Wookey","year":"1998","unstructured":"Wookey PJ, Cooper ME. Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension. Clin Exp Pharmacol Physiol. 1998;25:653\u201360.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1733_CR82","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1210\/jc.2006-1980","volume":"92","author":"A Novials","year":"2007","unstructured":"Novials A, Rodriguez-Ma\u00f1as L, Chico A, El Assar M, Casas S, Gomis R. Amylin and hypertension: association of an amylin-G132A gene mutation and hypertension in humans and amylin-induced endothelium dysfunction in rats. J Clin Endocrinol Metab. 2007;92:1446\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"1733_CR83","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1038\/oby.2007.239","volume":"15","author":"T Reinehr","year":"2007","unstructured":"Reinehr T, de Sousa G, Niklowitz P, Roth CL. Amylin and its relation to insulin and lipids in obese children before and after weight loss. Obesity (Silver Spring). 2007;15:2006\u201311.","journal-title":"Obesity (Silver Spring)"},{"key":"1733_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.617400\/full","author":"DS Mathiesen","year":"2021","unstructured":"Mathiesen DS, Lund A, Vilsb\u00f8ll T, Knop FK, Bagger JI. Amylin and calcitonin: potential therapeutic strategies to reduce body weight and liver fat. Front Endocrinol. 2021. https:\/\/doi.org\/10.3389\/fendo.2020.617400\/full.","journal-title":"Front Endocrinol"},{"key":"1733_CR85","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1083\/jcb.200312135","volume":"164","author":"R Dacquin","year":"2004","unstructured":"Dacquin R, Davey RA, Laplace C, et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol. 2004;164:509\u201314.","journal-title":"J Cell Biol"},{"key":"1733_CR86","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1359\/jbmr.2001.16.5.958","volume":"16","author":"M-N Horcajada-Molteni","year":"2001","unstructured":"Horcajada-Molteni M-N, Chanteranne B, Lebecque P, et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res. 2001;16:958\u201365.","journal-title":"J Bone Miner Res"},{"key":"1733_CR87","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.mce.2012.11.013","volume":"365","author":"I Guti\u00e9rrez-Rojas","year":"2013","unstructured":"Guti\u00e9rrez-Rojas I, Lozano D, Nuche-Berenguer B, et al. Amylin exerts osteogenic actions with different efficacy depending on the diabetic status. Mol Cell Endocrinol. 2013;365:309\u201315.","journal-title":"Mol Cell Endocrinol"},{"key":"1733_CR88","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.neuropharm.2017.03.030","volume":"119","author":"H Zhu","year":"2017","unstructured":"Zhu H, Xue X, Wang E, et al. Amylin receptor ligands reduce the pathological cascade of Alzheimer\u2019s disease. Neuropharmacology. 2017;119:170\u201381.","journal-title":"Neuropharmacology"},{"key":"1733_CR89","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/mp.2014.17","volume":"20","author":"H Zhu","year":"2015","unstructured":"Zhu H, Wang X, Wallack M, et al. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer\u2019s disease. Mol Psychiatry. 2015;20:252\u201362.","journal-title":"Mol Psychiatry"},{"key":"1733_CR90","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3233\/JAD-160677","volume":"56","author":"E Wang","year":"2017","unstructured":"Wang E, Zhu H, Wang X, et al. Amylin treatment reduces neuroinflammation and ameliorates abnormal patterns of gene expression in the cerebral cortex of an Alzheimer\u2019s disease mouse model. J Alzheimers Dis. 2017;56:47\u201361.","journal-title":"J Alzheimers Dis"},{"key":"1733_CR91","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.neurobiolaging.2013.10.076","volume":"35","author":"BL Adler","year":"2014","unstructured":"Adler BL, Yarchoan M, Hwang HM, et al. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer\u2019s disease pathogenesis and cognition. Neurobiol Aging. 2014;35:793\u2013801.","journal-title":"Neurobiol Aging"},{"key":"1733_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2021.113668","volume":"244","author":"KD Laugero","year":"2022","unstructured":"Laugero KD, Tryon M, Mack C, et al. Peripherally administered amylin inhibits stress-like behaviors and enhances cognitive performance. Physiol Behav. 2022;244:113668.","journal-title":"Physiol Behav"},{"key":"1733_CR93","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/ejp.898","volume":"20","author":"CS Potes","year":"2016","unstructured":"Potes CS, Pestana AC, Pontes M, Caramelo AS, Neto FL. Amylin modulates the formalin-induced tonic pain behaviours in rats. Eur J Pain. 2016;20:1741\u201352.","journal-title":"Eur J Pain"},{"key":"1733_CR94","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.neuroscience.2009.11.063","volume":"165","author":"X Huang","year":"2010","unstructured":"Huang X, Yang J, Chang JK, Dun NJ. Amylin suppresses acetic acid-induced visceral pain and spinal c-fos expression in the mouse. Neuroscience. 2010;165:1429\u201338.","journal-title":"Neuroscience"},{"key":"1733_CR95","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s10194-024-01744-z","volume":"25","author":"TA Rees","year":"2024","unstructured":"Rees TA, Tasma Z, Garelja ML, O\u2019Carroll SJ, Walker CS, Hay DL. Calcitonin receptor, calcitonin gene-related peptide and amylin distribution in C1\/2 dorsal root ganglia. J Headache Pain. 2024;25:36.","journal-title":"J Headache Pain"},{"key":"1733_CR96","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1530\/EJE-21-1261","volume":"186","author":"DS Mathiesen","year":"2022","unstructured":"Mathiesen DS, Lund A, Holst JJ, Knop FK, Lutz TA, Bagger JI. Therapy of endocrine disease: amylin and calcitonin\u2014physiology and pharmacology. Eur J Endocrinol. 2022;186:R93-111.","journal-title":"Eur J Endocrinol"},{"key":"1733_CR97","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/endrev\/bnab034","volume":"43","author":"AM Angelidi","year":"2022","unstructured":"Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. Novel noninvasive approaches to the treatment of obesity: from pharmacotherapy to gene therapy. Endocr Rev. 2022;43:507\u201357. https:\/\/doi.org\/10.1210\/endrev\/bnab034.","journal-title":"Endocr Rev"},{"key":"1733_CR98","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1243","volume":"12","author":"I Rubini\u0107","year":"2024","unstructured":"Rubini\u0107 I, Kurtov M, Liki\u0107 R. Novel pharmaceuticals in appetite regulation: exploring emerging gut peptides and their pharmacological prospects. Pharmacol Res Perspect. 2024;12:e1243.","journal-title":"Pharmacol Res Perspect"},{"key":"1733_CR99","doi-asserted-by":"publisher","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","volume":"307","author":"KV Andreassen","year":"2014","unstructured":"Andreassen KV, Feigh M, Hjuler ST, Gydesen S, Henriksen JE, Beck-Nielsen H, et al. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. Am J Physiol Endocrinol Metab. 2014;307:E24-33.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1733_CR100","doi-asserted-by":"publisher","first-page":"36621","DOI":"10.1074\/jbc.M006170200","volume":"275","author":"RG Bennett","year":"2000","unstructured":"Bennett RG, Duckworth WC, Hamel FG. Degradation of amylin by insulin-degrading enzyme. J Biol Chem. 2000;275:36621\u20135.","journal-title":"J Biol Chem"},{"key":"1733_CR101","doi-asserted-by":"publisher","first-page":"E620","DOI":"10.1152\/ajpendo.00217.2007","volume":"293","author":"SR Smith","year":"2007","unstructured":"Smith SR, Blundell JE, Burns C, Ellero C, Schroeder BE, Kesty NC, et al. Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study. Am J Physiol Endocrinol Metab. 2007;293:E620-627.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1733_CR102","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.2337\/dc08-0029","volume":"31","author":"SR Smith","year":"2008","unstructured":"Smith SR, Aronne LJ, Burns CM, Kesty NC, Halseth AE, Weyer C. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care. 2008;31:1816\u201323.","journal-title":"Diabetes Care"},{"key":"1733_CR103","doi-asserted-by":"crossref","unstructured":"Ryan G, Jobe L, Briscoe T. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther. 2008;2:203-14.","DOI":"10.2147\/DDDT.S3225"},{"key":"1733_CR104","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1210\/jc.2008-2580","volume":"94","author":"RA Heptulla","year":"2009","unstructured":"Heptulla RA, Rodriguez LM, Mason KJ, Haymond MW. Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. J Clin Endocrinol Metab. 2009;94:1608\u201311.","journal-title":"J Clin Endocrinol Metab"},{"key":"1733_CR105","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2337\/dc19-1922","volume":"43","author":"A Haidar","year":"2020","unstructured":"Haidar A, Tsoukas MA, Bernier-Twardy S, et al. A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial. Diabetes Care. 2020;43:597\u2013606. https:\/\/doi.org\/10.2337\/dc19-1922.","journal-title":"Diabetes Care"},{"key":"1733_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/2.00015","volume":"1","author":"I Idris","year":"2023","unstructured":"Idris I. Novel development of a co-formulation of insulin and amylin. Diabetes Obes Metab. 2023;1:e00015. https:\/\/doi.org\/10.1002\/2.00015.","journal-title":"Diabetes Obes Metab"},{"key":"1733_CR107","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/17434440.2024.2406901","volume":"21","author":"N Kadiyala","year":"2024","unstructured":"Kadiyala N, Hovorka R, Boughton CK. Closed-loop systems: recent advancements and lived experiences. Expert Rev Med Devices. 2024;21:927\u201341. https:\/\/doi.org\/10.1080\/17434440.2024.2406901.","journal-title":"Expert Rev Med Devices"},{"key":"1733_CR108","doi-asserted-by":"crossref","unstructured":"Tsoukas MA, Majdpour D, Yale J-F, et al. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial. Lancet Digit Health. 2021;3:e723\u201332. https:\/\/www.thelancet.com\/journals\/landig\/article\/PIIS2589-7500(21)00139-4\/fulltext.","DOI":"10.1016\/S2589-7500(21)00139-4"},{"key":"1733_CR109","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jcjd.2021.02.002","volume":"45","author":"D Majdpour","year":"2021","unstructured":"Majdpour D, Tsoukas MA, Yale J-F, El Fathi A, Rutkowski J, Rene J, et al. Fully automated artificial pancreas for adults with type 1 diabetes using multiple hormones: exploratory experiments. Can J Diabetes. 2021;45:734\u201342.","journal-title":"Can J Diabetes"},{"key":"1733_CR110","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","volume":"21","author":"RE Ratner","year":"2004","unstructured":"Ratner RE, Dickey R, Fineman M, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204\u201312.","journal-title":"Diabet Med"},{"issue":"34","key":"1733_CR111","first-page":"385","volume":"2010","author":"CM Mack","year":"2005","unstructured":"Mack CM, Soares CJ, Wilson JK, Athanacio JR, Turek VF, Trevaskis JL, et al. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes. 2005;2010(34):385\u201395.","journal-title":"Int J Obes"},{"key":"1733_CR112","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1124\/jpet.121.000567","volume":"377","author":"MM Fletcher","year":"2021","unstructured":"Fletcher MM, Keov P, Truong TT, Mennen G, Hick CA, Zhao P, et al. AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists. J Pharmacol Exp Ther. 2021;377:417\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"1733_CR113","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160\u201372.","journal-title":"Lancet"},{"key":"1733_CR114","unstructured":"AstraZeneca. Our pipeline. https:\/\/www.astrazeneca.com\/our-therapy-areas\/pipeline.html. Accessed 3 Mar 2025."},{"key":"1733_CR115","unstructured":"Mather K, et al. Long acting amylin receptor agonist, AZD6234, shows advantages over GLP-1 receptor agonist activation for leptin re-sensitization in a diet-induced obese (DIO) rat model. In: ObesityWeek 2024, 2\u20136 November 2024, San Antonio. Poster 576."},{"key":"1733_CR116","unstructured":"Zealand Pharma. Petrelintide. https:\/\/www.zealandpharma.com\/pipeline\/petrelintide\/. Accessed 3 Mar 2025."},{"key":"1733_CR117","unstructured":"Axelsen M, Sidhu S. A study in healthy male volunteers to look at the safety and tolerability of the new test medicine GUB014295 and how it is taken up by the body when given as a single dose by injection. https:\/\/www.isrctn.com\/ISRCTN85112396. Accessed 3 Mar 2025."},{"key":"1733_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y","author":"E Melson","year":"2024","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024. https:\/\/doi.org\/10.1038\/s41366-024-01473-y.","journal-title":"Int J Obes (Lond)"},{"key":"1733_CR119","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12902-020-00678-2","volume":"21","author":"AT Larsen","year":"2021","unstructured":"Larsen AT, Gydesen S, Sonne N, Karsdal MA, Henriksen K. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile. BMC Endocr Disord. 2021;21:10.","journal-title":"BMC Endocr Disord"},{"key":"1733_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114969","volume":"164","author":"AT Larsen","year":"2023","unstructured":"Larsen AT, Melander SA, Sonne N, et al. Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss. Biomed Pharmacother Biomed Pharmacother. 2023;164: 114969.","journal-title":"Biomed Pharmacother Biomed Pharmacother"},{"key":"1733_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11892-015-0693-3","volume":"16","author":"T Jorsal","year":"2016","unstructured":"Jorsal T, Rungby J, Knop FK, Vilsb\u00f8ll T. GLP-1 and amylin in the treatment of obesity. Curr Diab Rep. 2016;16:1.","journal-title":"Curr Diab Rep"},{"key":"1733_CR122","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(21)00944-2","volume":"397","author":"S Becerril","year":"2021","unstructured":"Becerril S, Fr\u00fchbeck G. Cagrilintide plus semaglutide for obesity management. Lancet. 2021;397:1687\u20139.","journal-title":"Lancet"},{"key":"1733_CR123","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736\u201348.","journal-title":"Lancet"},{"key":"1733_CR124","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402:720\u201330.","journal-title":"Lancet"},{"key":"1733_CR125","unstructured":"Novo Nordisk A\/S. CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=915082. Accessed 3 Mar 2025."},{"key":"1733_CR126","unstructured":"Novo Nordisk Global. R&D pipeline. https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/science-and-technology\/r-d-pipeline.html. Accessed 3 Mar 2025."},{"key":"1733_CR127","unstructured":"Gasiorek A, Heydorn A, Kirkeby K, et al. Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study. 2024. https:\/\/www.easd.org\/media-centre\/home.html#!resources\/b-safety-tolerability-and-weight-reduction-findings-of-oral-amycretin-a-novel-amylin-and-glucagon-like-peptide-1-receptor-co-agonist-in-a-first-in-human-study-b. Accessed"},{"key":"1733_CR128","unstructured":"Healthline. In early study, people on weight loss pill lost 13% of their body weight. 2024. Available from: https:\/\/www.healthline.com\/health-news\/in-early-study-people-on-weight-loss-pill-lost-13-of-their-body-weight. Accessed 8 Dec 2024."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01733-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01733-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01733-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:03:32Z","timestamp":1747458212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01733-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1733"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01733-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have given lectures, received honoraria and research support and participated in conferences, advisory boards and clinical trials sponsored by many pharmaceutical companies. However, no pharmaceutical company played any role in the scientific content of the present article, which has been written independently and reflects only the opinions of the authors, without no imput from the pharmaceutical industry. The following conflict of interests are reported. \u0160pela Vol\u010dan\u0161ek has received lecture honoraria from Novo Nordisk, Eli Lilly, Medtronic, Abbott, AstraZeneca and Boehringer Ingelheim. Andrijana Koceva reports receiving lecture honoraria from Novo Nordisk, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Medtronic and Pfizer. Mojca Jensterle has received lecture honoraria from Novo Nordisk, Eli Lilly, Pfizer, Amgen, Novartis and Sanofi, and is an advisory board member of Novo Nordisk, Eli Lilly, Amgen and Pfizer. Andrej Jane\u017e has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Medtronic, Abbott, Novo Nordisk, Novartis and Swixx. Emir Muzurovi\u0107 has given lectures and participated in conferences and advisory boards sponsored by several pharmaceutical companies, including Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Medtronic and Servier.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}